Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 355 entries
Sorted by: Best Match Show Resources per page
Literature review on transitions across early childhood and compulsory school settings in Europe

out of school settings

Balduzzi L.
GSID: ZsXD6ZcADgAJ
L Balduzzi, A Lazzari, K Van Laere, C Boudry, M Rezek… - 2019 - amsacta.unibo.it

… The aim of this literature review, conducted as part of the START project, is to deepen the understanding of transitions across ECEC settings – and between these and CSE settings – by critically analysing the findings of empirical...

Cite
Balduzzi, L., Lazzari, A., Van Laere, K., Boudry, C., Rezek, M., Mlinar, M., & McKinnon, E. (2019). Literature review on transitions across early childhood and compulsory school settings in Europe.
Balduzzi, Lucia, et al. "Literature review on transitions across early childhood and compulsory school settings in Europe." (2019).
Copy Download .nbib Format: MLA
Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites.

Future science OA

Galluzzi L, Diotallevi A, Magnani M.
PMID: 28883998
Future Sci OA. 2017 May 12;3(3):FSO198. doi: 10.4155/fsoa-2017-0020. eCollection 2017 Aug.

Perturbations of the physiological status of the endoplasmic reticulum (ER) trigger a specific response known as the ER stress response or unfolded protein response (UPR). In mammalian cells, the UPR is mediated by three ER transmembrane proteins (IRE1, PERK...

Cite
Galluzzi L, Diotallevi A, Magnani M. Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites. Future Sci OA. 2017;3(3):FSO198doi: 10.4155/fsoa-2017-0020.
Galluzzi, L., Diotallevi, A., & Magnani, M. (2017). Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites. Future science OA, 3(3), FSO198. https://doi.org/10.4155/fsoa-2017-0020
Galluzzi, Luca, et al. "Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites." Future science OA vol. 3,3 (2017): FSO198. doi: https://doi.org/10.4155/fsoa-2017-0020
Galluzzi L, Diotallevi A, Magnani M. Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites. Future Sci OA. 2017 May 12;3(3):FSO198. doi: 10.4155/fsoa-2017-0020. eCollection 2017 Aug. PMID: 28883998; PMCID: PMC5583660.
Copy Download .nbib Format: NLM
Doubling the blockade for melanoma immunotherapy.

Oncoimmunology

Galluzzi L, Eggermont A, Kroemer G.
PMID: 26942094
Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016.

No abstract available.

Cite
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015;5(1):e1106127doi: 10.1080/2162402X.2015.1106127.
Galluzzi, L., Eggermont, A., & Kroemer, G. (2016). Doubling the blockade for melanoma immunotherapy. Oncoimmunology, 5(1), e1106127. https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi, Lorenzo, et al. "Doubling the blockade for melanoma immunotherapy." Oncoimmunology vol. 5,1 (2016): e1106127. doi: https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016. PMID: 26942094; PMCID: PMC4760293.
Copy Download .nbib Format: NLM
Trial watch: Naked and vectored DNA-based anticancer vaccines.

Oncoimmunology

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26155408
Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is...

Cite
Bloy N, Buqué A, Aranda F, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4(5):e1026531doi: 10.1080/2162402X.2015.1026531.
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology, 4(5), e1026531. https://doi.org/10.1080/2162402X.2015.1026531
Bloy, Norma, et al. "Trial watch: Naked and vectored DNA-based anticancer vaccines." Oncoimmunology vol. 4,5 (2015): e1026531. doi: https://doi.org/10.1080/2162402X.2015.1026531
Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. PMID: 26155408; PMCID: PMC4485755.
Copy Download .nbib Format: NLM
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Oncoimmunology

Kroemer G, Galluzzi L.
PMID: 26140249
Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul.

Results from recent clinical trials demonstrate that a combinatorial immunotherapeutic regimen based on 2 distinct checkpoint blockers, namely, the CTLA4-targeting agent ipilimumab and the PD-1-specific molecule nivolumab, causes objective responses in a majority of subjects with advanced melanoma. These...

Cite
Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015;4(7):e1058037doi: 10.1080/2162402X.2015.1058037.
Kroemer, G., & Galluzzi, L. (2015). Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology, 4(7), e1058037. https://doi.org/10.1080/2162402X.2015.1058037
Kroemer, Guido, and Galluzzi, Lorenzo. "Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark." Oncoimmunology vol. 4,7 (2015): e1058037. doi: https://doi.org/10.1080/2162402X.2015.1058037
Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul. PMID: 26140249; PMCID: PMC4485790.
Copy Download .nbib Format: NLM
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?.

Oncoimmunology

Kroemer G, Galluzzi L, Zitvogel L, Fridman WH.
PMID: 26140250
Oncoimmunology. 2015 Jun 05;4(7):e1058597. doi: 10.1080/2162402X.2015.1058597. eCollection 2015 Jul.

The first study demonstrating that human colorectal carcinoma (CRC) is under robust immunosurveillance was published a decade ago. Today, it is clear that CRC patients with Stage III lesions abundantly infiltrated by effector memory T cells have a better...

Cite
Kroemer G, Galluzzi L, Zitvogel L, et al. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology. 2015;4(7):e1058597doi: 10.1080/2162402X.2015.1058597.
Kroemer, G., Galluzzi, L., Zitvogel, L., & Fridman, W. H. (2015). Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology, 4(7), e1058597. https://doi.org/10.1080/2162402X.2015.1058597
Kroemer, Guido, et al. "Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?." Oncoimmunology vol. 4,7 (2015): e1058597. doi: https://doi.org/10.1080/2162402X.2015.1058597
Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology. 2015 Jun 05;4(7):e1058597. doi: 10.1080/2162402X.2015.1058597. eCollection 2015 Jul. PMID: 26140250; PMCID: PMC4485723.
Copy Download .nbib Format: NLM
Magnetic Resonance Enterography Findings of Intestinal Behçet Disease in a Child.

Case reports in radiology

D'Angelo T, Gallizzi R, Romano C, Cicero G, Mazziotti S.
PMID: 28630777
Case Rep Radiol. 2017;2017:8061648. doi: 10.1155/2017/8061648. Epub 2017 May 24.

Behçet's disease (BD) is a multisystem disorder of unknown aetiology, characterized by recurrent oral ulcers, genital ulcers, uveitis, skin lesions, and pathergy. Gastrointestinal disease outside the oral cavity is well recognized and usually takes the form of small intestinal...

Cite
D'Angelo T, Gallizzi R, Romano C, et al. Magnetic Resonance Enterography Findings of Intestinal Behçet Disease in a Child. Case Rep Radiol. 2017;2017:8061648doi: 10.1155/2017/8061648.
D'Angelo, T., Gallizzi, R., Romano, C., Cicero, G., & Mazziotti, S. (2017). Magnetic Resonance Enterography Findings of Intestinal Behçet Disease in a Child. Case reports in radiology, 20178061648. https://doi.org/10.1155/2017/8061648
D'Angelo, Tommaso, et al. "Magnetic Resonance Enterography Findings of Intestinal Behçet Disease in a Child." Case reports in radiology vol. 2017 (2017): 8061648. doi: https://doi.org/10.1155/2017/8061648
D'Angelo T, Gallizzi R, Romano C, Cicero G, Mazziotti S. Magnetic Resonance Enterography Findings of Intestinal Behçet Disease in a Child. Case Rep Radiol. 2017;2017:8061648. doi: 10.1155/2017/8061648. Epub 2017 May 24. PMID: 28630777; PMCID: PMC5463125.
Copy Download .nbib Format: NLM
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25949870
Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal...

Cite
Vacchelli E, Pol J, Bloy N, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4(1):e985940doi: 10.4161/2162402X.2014.985940.
Vacchelli, E., Pol, J., Bloy, N., Eggermont, A., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology, 4(1), e985940. https://doi.org/10.4161/2162402X.2014.985940
Vacchelli, Erika, et al. "Trial watch: Tumor-targeting monoclonal antibodies for oncological indications." Oncoimmunology vol. 4,1 (2015): e985940. doi: https://doi.org/10.4161/2162402X.2014.985940
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. PMID: 25949870; PMCID: PMC4368132.
Copy Download .nbib Format: NLM
Linear psoriasis following the typical distribution of the sciatic nerve.

Journal of dermatological case reports

Galluzzo M, Talamonti M, Di Stefani A, Chimenti S.
PMID: 25932056
J Dermatol Case Rep. 2015 Mar 31;9(1):6-11. doi: 10.3315/jdcr.2015.1189. eCollection 2015 Mar 31.

BACKGROUND: Some studies suggest that the nervous system plays a role in the onset of psoriasis and psoriasis flares including the symmetry of lesions, sparing of denervated skin and the role of stress in inducing lesions.MAIN OBSERVATIONS: We describe...

Cite
Galluzzo M, Talamonti M, Di Stefani A, et al. Linear psoriasis following the typical distribution of the sciatic nerve. J Dermatol Case Rep. 2015;9(1):6-11doi: 10.3315/jdcr.2015.1189.
Galluzzo, M., Talamonti, M., Di Stefani, A., & Chimenti, S. (2015). Linear psoriasis following the typical distribution of the sciatic nerve. Journal of dermatological case reports, 9(1), 6-11. https://doi.org/10.3315/jdcr.2015.1189
Galluzzo, Marco, et al. "Linear psoriasis following the typical distribution of the sciatic nerve." Journal of dermatological case reports vol. 9,1 (2015): 6-11. doi: https://doi.org/10.3315/jdcr.2015.1189
Galluzzo M, Talamonti M, Di Stefani A, Chimenti S. Linear psoriasis following the typical distribution of the sciatic nerve. J Dermatol Case Rep. 2015 Mar 31;9(1):6-11. doi: 10.3315/jdcr.2015.1189. eCollection 2015 Mar 31. PMID: 25932056; PMCID: PMC4410884.
Copy Download .nbib Format: NLM
ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE.

Journal of biological regulators and homeostatic agents

Romano' CL, Gallazzi E, Logoluso N, De Vecchi E, Drago L.
PMID: 26652496
J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):103-10.

Bone and joint infections are a difficult to treat condition, often associated with bone loss. Although the management of septic bone defects may currently be achieved through various treatment modalities, there is a continuous need for bone substitutes able...

Cite
Romano' CL, Gallazzi E, Logoluso N, et al. ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE. J Biol Regul Homeost Agents. 2015;29(4):103-10
Romano', C. L., Gallazzi, E., Logoluso, N., De Vecchi, E., & Drago, L. (2015). ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE. Journal of biological regulators and homeostatic agents, 29(4), 103-10.
Romano', C L, et al. "ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE." Journal of biological regulators and homeostatic agents vol. 29,4 (2015): 103-10.
Romano' CL, Gallazzi E, Logoluso N, De Vecchi E, Drago L. ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE. J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):103-10. PMID: 26652496.
Copy Download .nbib Format: NLM
Trial watch: Dendritic cell-based anticancer therapy.

Oncoimmunology

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25941593
Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov.

The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell...

Cite
Bloy N, Pol J, Aranda F, et al. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014;3(11):e963424doi: 10.4161/21624011.2014.963424.
Bloy, N., Pol, J., Aranda, F., Eggermont, A., Cremer, I., Fridman, W. H., Fučíková, J., Galon, J., Tartour, E., Spisek, R., Dhodapkar, M. V., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology, 3(11), e963424. https://doi.org/10.4161/21624011.2014.963424
Bloy, Norma, et al. "Trial watch: Dendritic cell-based anticancer therapy." Oncoimmunology vol. 3,11 (2014): e963424. doi: https://doi.org/10.4161/21624011.2014.963424
Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov. PMID: 25941593; PMCID: PMC4292311.
Copy Download .nbib Format: NLM
Molecular and Cellular Oncology: A new journal for a changing field.

Molecular & cellular oncology

Galluzzi L, Kroemer G.
PMID: 27308308
Mol Cell Oncol. 2014 May 01;1(1):e29052. doi: 10.4161/mco.29052. eCollection 2014.

No abstract available.

Cite
Galluzzi L, Kroemer G. Molecular and Cellular Oncology: A new journal for a changing field. Mol Cell Oncol. 2014;1(1):e29052doi: 10.4161/mco.29052.
Galluzzi, L., & Kroemer, G. (2014). Molecular and Cellular Oncology: A new journal for a changing field. Molecular & cellular oncology, 1(1), e29052. https://doi.org/10.4161/mco.29052
Galluzzi, Lorenzo, and Kroemer, Guido. "Molecular and Cellular Oncology: A new journal for a changing field." Molecular & cellular oncology vol. 1,1 (2014): e29052. doi: https://doi.org/10.4161/mco.29052
Galluzzi L, Kroemer G. Molecular and Cellular Oncology: A new journal for a changing field. Mol Cell Oncol. 2014 May 01;1(1):e29052. doi: 10.4161/mco.29052. eCollection 2014. PMID: 27308308; PMCID: PMC4905166.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 355 entries